Due of Antibiotics in Pediatric LRTI Patients

Authors
Anusha Yerraboina*, Varun Tripuraneni, Hemavathi Neelamshetti
Intern, Department of Pharm. D, Malla Reddy Narayana Multi Specialty Hospital, Hyderabad
Corresponding Author
Anusha Yerraboina*
1-1-241/143, Plot 5, Bhavani Nagar Colony, Kapra, ECIL, Secunderabad- 500062
Email: anushapharmd1@gmail.com, Phone Num: 8801654126

ABSTRACT
DUE is an ongoing, systematic process designed to maintain the appropriate and effective uses of drugs. DUE may be applied to a drug or therapeutic class, or diagnosis. DUE is typically classified into three different categories: prospective, concurrent and retrospective. Drugs prescribed for children are the same as those originally developed for adults. However, growth and development processes in children, in addition to disease profile, might expose them to different adverse effects. This study aimed at understanding drug utilization patterns in pediatric patients at a tertiary care hospital in Hyderabad. A prospective study was carried out on 106 pediatric patients diagnosed to have LRTI. It was found that the third generation Cephalosporins was the most commonly prescribed, ceftriaxone being the highest among all. This study focused on the analysis of prescriptions in the management of LRTI in pediatric patients.

Keywords: Cephalosporins, DUE, LRTI, Pediatric patients.

INTRODUCTION
Drug utilization research was defined by WHO in 1977 as the marketing, distribution, prescription, and use of drugs in a society, with special emphasis on the resulting medical, social and economic consequences. A modern definition of pharmacoepidemiology is: “the study of the use and effects/side effects of drugs in large numbers of people with the purpose of supporting the rational and cost-effective use of drugs in the population thereby improving health outcomes”
Together, drug utilization research and pharmacy-epidemiology may provide insights into the following aspects of drug use and drug prescribing

DUE is an ongoing, systematic process designed to maintain the appropriate and effective uses of drugs. DUE is typically classified into three different categories: prospective, concurrent and retrospective.
Prospective involves evaluating a patient’s planned drug therapy before a medication is dispensed. Pharmacists routinely perform prospective reviews by assessing a prescription medication's dosage and its directions and reviewing patient information for possible drug interactions or duplicate therapy. Concurrent is performed during the course of treatment and involves the ongoing monitoring of drug therapy to ensure positive outcomes.
A retrospective DUE is the simplest to perform since drug therapy is reviewed after the patient has received the medication [4].

DUE is a performance improvement method that focuses on evaluating and improving drug use processes to achieve optimal patient outcomes. DUE may be applied to a drug or therapeutic class, or diagnosis [5].

Markets for children's medicines tend to be small and the range of doses used may be wide for any drug formulation because many drugs prescribed widely for infants and children are not available in suitable dosage forms, leading to a lack of attention to pediatric medicines [6].

The present study aimed to evaluate the use of antibiotics in pediatric patients with LRTI and promote the rational medication use.

**METHODOLOGY**

A prospective observational study has been conducted in the pediatric department of tertiary care hospitals, Hyderabad. The study was carried out for a period of seven months. All pediatric patients who were diagnosed to have LRTI and required hospitalization for a minimum of 2 days were included in the study. Out-patients, patients with HIV positive status and whose care takers are not willing to give the consent were excluded. Structurally designed data collection form was used to record the patient’s data such as demographics, lab investigations, treatment and progress.

**RESULTS**

**Gender wise distribution of the patients**

A total of 106 patients were enrolled during the study period among which 56 (52.8%) were males and the rest 50 (47.2%) were females.

**Age wise distribution of patients**

Out of 106 patients, about 46 (43.3%) were infants, 39 (36.8%) were young child, 17 (16.0%) were child and 4 (3.7%) were adolescents.

| Category  | Age            | Number of Patients | Percentage |
|-----------|----------------|--------------------|------------|
| Neonates  | 0-28 days      | 00                 | 0          |
| Infants   | 2-24 months    | 46                 | 43.4%      |
| Young child | 2-6 years    | 39                 | 36.8%      |
| Child     | 6-12 years     | 17                 | 16.0%      |
| Adolescent| 12-16 years    | 4                  | 3.8%       |

**Duration of hospital stay**

Out of 106 patients, most of them stayed in the range of 2-4 days 53(50%) followed by 5-7 (43.4%) and others were summarized in the table as follows. Average stay per patient was 4.66 days

| Duration of hospital stays (days) | Number of patients (%) |
|----------------------------------|------------------------|
| 2-4                              | 53(50)                 |
| 5-7                              | 46(43.4)               |
| >8                               | 7(6.79)                |

**Number of drugs**

Out of 106 patients, most of the patients were prescribed with 5-7 drugs (46.3%) followed by 8-10 drugs (29.2%) and others were summarized in the table as follows

| Number of drugs | Number of patients (%) |
|-----------------|------------------------|
| 2-4             | 14(13.2)               |
| 5-7             | 49(46.3)               |
| 8-10            | 31(29.2)               |
| >11             | 12(11.3)               |

**Number of Co-morbidities**

Out of 106 patients, about 26 had comorbid conditions among which 6 were GI disorders and 2 had seizures. No multiple comorbidities were seen.
Table 4: No of co-morbidities

| Co-morbidities | 24(22.6%) |
|----------------|----------|
| No co-morbidities | 82(77.4%) |

**Disease distribution**

Out of 106 patients, 55 were diagnosed with non-specific LRTI, 33 had pneumonia and rest were summarised in the table.

Table 5: Disease distribution

| Disease Condition         | Number of patients (%) |
|---------------------------|------------------------|
| Pneumonia                 | 33(31.1)               |
| Bronchiolitis             | 15(14.2)               |
| Bronchitis                | 3(2.8)                 |
| Non-specific LRTI         | 54(50.9)               |

**Distribution of anti-microbial agent**

Among all the enlisted population 3rd generation Cephalosporins were most widely prescribed.

Table 6: Distribution of Antimicrobial Agents

| AMA                     | ATC       | NUM |
|-------------------------|-----------|-----|
| PIPERACILLIN + TAZOBACTUM | J01CA12   | 9   |
| AMPICILLIN              | J01CR01   | 3   |
| AMOXICILLIN+CLAVULANIC  | J01CR02   | 21  |
| ACID                    |           |     |
| CEFTRIAXONE             | J01DD04   | 51  |
| CEFIXIME                | J01DD08   | 9   |
| CEFOTAXIME              | J01DD01   | 20  |
| CEPFODOXIME             | J01DD13   | 12  |
| AZITHROMYCIN            | J01FA10   | 17  |
| CLARITHROMYCIN          | J01FA09   | 1   |
| OFLOXACIN               | J01MA01   | 2   |
| CIPROFLOXACIN           | J01MA02   | 1   |
| AMIKACIN                | J01GB06   | 25  |

**DISCUSSION**

Drug utilization is defined by the WHO as the “marketing, distribution, prescription, and use of drugs in society, with special emphasis on the resulting medical, social, and economic consequences” [7]. Pharmacists participating in DUR programs can directly improve the quality of care for patients, individually and as populations, by striving to prevent the use of unnecessary or inappropriate drug therapy, prevent adverse drug reactions and improve overall drug effectiveness [8].

In our study a total of 106 patients were recruited out of which 56 (52.8%) were males and the rest 50 (47.2%) were females. About 46 (43.3%) were infants, 39(36.8%) were young child, 17(16.0%) were child and 4(3.7%) were adolescents and the detailed age wise classification of patients were shown in table 1.2. Among these patients 55 were diagnosed with non-specific LRTI, 33 had pneumonia and rest was summarized in the table above. These 106 patients were treated with wide variety of antibiotic classes such as penicillins, cephalosporins, macrolides, aminoglycosides, flouroquinolones. A total of 11 drugs from these different classes of drugs were used in the therapy for children. Third generation cephalosporins were the highly prescribed among all other medications ceftriaxone being the widely used next to amoxicillin.

**CONCLUSION**

The present DUE study focused on the analysis of prescriptions observed in the management of LRTI of pediatric patients of a tertiary care hospital. The study revealed ceftriaxone to be the drug being widely used. The study also focuses on the optimal use of antibiotics in the pediatric ward. Several strategies and guidelines have to be followed to promote the rational, optimal and safe use of drugs.

**ACKNOWLEDGEMENT**

I firstly thank the Almighty for giving me the strength to take this project till completion and overcome all the challenges I faced during the completion of project. I thank my parents have been a great support to me in all regards. I express my heartfelt thanks to our guide, Dr. Sadanandam Akari, Assistant Professor, Malla Reddy Institute of Pharmaceutical Sciences, for his guidance. Lastly, I would also extend my deep gratitude to Dr. Sukesh Krishna Chaitanya Loka, Clinical Pharmacist, Apollo Cancer Institutes, without who’s helping hand, this article wouldn’t have emerged out.
REFERENCES

1. Rajesh Kumar Suman, Ipseeta Ray Mohanty, Y A Deshmukh. The concepts of Drug Utilization Study, Vol : 3, Issue : 10,352-363

2. Sathvik BS., Drug utilization review/evaluation, in Parthasarathi G, Nyfon-Hansen K, Nahata MC (eds), A textbook of clinical pharmacy practice. 1st ed., orient Longman, India, 362-375, 2004

3. Sukesh Krishna Chaitanya Loka et al. Evaluation of Beta blockers use at a tertiary care hospital. Indo American Journal of Pharm Research 2015:5(07).

4. Shalini S, Ravichandran V, Mohanty BK, Dhanaraj SK, Saraswati R. Drug utilization studies – an overview. Intern J Pharma Sci Nanotech 2010; 3(1): 803-10.

5. Lemecha Diriba, Fikru Worku, Tsinuel Girma. Evaluation of prophylactic use of cotromoxazole for people living with HIV/AIDS in Jimma University specialized hospital, Southwest Ethiopia. Ethiop J Health Sciences 2008; 18(3):59-64.

6. You ML, Chun Y, Yung TK, Man YH, Hsiang YC. Outcomes of pharmacy interventions on pediatric medication prescribing patterns in Taiwan. Int J Clin Exp Med. 2010; 2:173–80.

7. Serradell J, Bjornson DC & Hartzema AG. Drug Utilization Study Methodologies: National and International Perspectives. Drug Intelligence and Clinical Pharmacy. 1987; 21(12, December):994-1001.

8. Navarro, Robert. Chapter 8: Drug Utilization Review Strategies. In Managed Care Pharmacy Practice, published 2008, pp. 215 –229.